REG - GSK PLC - GSK announces additional EAGLE-1 results

GSKAnnouncement

17/04/2024 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240417:nRSQ8523Ka&default-theme=true

RNS Number : 8523K  GSK PLC  17 April 2024

Issued: 17 April 2024, London UK

 

EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment
option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to
existing treatments

 

·   Gepotidacin achieved a 92.6% microbiological success rate and was
non-inferior to the leading combination treatment

·   EAGLE-1 is the third positive pivotal trial for gepotidacin, a
potential first-in-class oral antibiotic as part of GSK's industry-leading
infectious diseases portfolio

·   Results will be presented at European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) Global

 

 

 

GSK plc (LSE/NYSE: GSK) today announced positive results from the pivotal
EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral
antibiotic with a novel mechanism of action for uncomplicated urogenital
gonorrhoea (GC) in adolescents and adults. These results will be presented on
30 April 2024 at the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) Global in Barcelona, Spain.

 

The results from EAGLE-1 are based on a primary endpoint of microbiological
response (success or failure of eliminating the bacterial cause of gonorrhoea)
at the Test-of-Cure (ToC) visit 3-7 days after treatment. The trial showed
that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6%
success rates when compared to 91.2% success rates for intramuscular (IM)
ceftriaxone (500mg) plus oral azithromycin (1,000mg) combined therapy, a
leading combination treatment regimen for gonorrhoea.

 

The safety and tolerability profile of gepotidacin in the EAGLE-1 trial was
consistent with results seen in phase I and II trials. The most commonly
reported adverse events (AEs) in gepotidacin subjects were gastrointestinal
(GI). All AEs were mild or moderate (Grade 1 or 2) except for one severe
(Grade 3), unrelated event in each treatment arm and one unrelated serious
event in the gepotidacin arm.

 

There are an estimated 82 million new cases of gonorrhoea globally each
year. 1  In the United States, rates of reported gonorrhoea have increased
118% from 2009 to 2021, 2  with 648,056 cases being reported to the US Centers
for Disease Control and Prevention (CDC) in 2022. 3  The CDC also reported
that approximately half of gonorrhoea cases each year in the US are resistant
to one antibiotic. 4 

 

Chris Corsico, SVP Development, GSK, said: "These results highlight the
potential of gepotidacin as a new oral treatment option given the rising
incidence of gonorrhoea worldwide including drug resistant infections. The
imperative for innovative treatments has never been clearer. We are committed
to working with health regulators globally to introduce this potential new
antibiotic, focusing on solutions that meet critical patient needs."

 

Gonorrhoea is a sexually transmitted infection caused by bacteria called
Neisseria gonorrhoeae, which has been recognised by the World Health
Organisation as a priority pathogen. It affects both men and women and if
inadequately treated, it can lead to infertility and other sexual and
reproductive health complications. It also increases the risk of HIV
infection.

 

GSK is also developing gepotidacin for the potential treatment of
uncomplicated urinary tract infections (uUTI). Positive phase III data from
the EAGLE-2 and EAGLE-3 trials were presented at the European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID) in April 2023, and
published in The Lancet
(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02196-7/abstract)
. 5  If approved, gepotidacin could be the first in a new class of oral
antibiotics in uUTI in over 20 years. EAGLE-1 is the third positive pivotal
trial for gepotidacin.

 

The development of gepotidacin has been funded in whole or in part with
federal funds from the US Department of Health and Human Services,
Administration for Strategic Preparedness and Response, Biomedical Advanced
Research and Development Authority (BARDA), under Other Transaction Agreement
number HHSO100201300011C and with federal funds awarded by the Defense Threat
Reduction Agency under agreement number HDTRA1-07-9-0002.

 

About the EAGLE (Efficacy of Antibacterial Gepotidacin Evaluated) phase III
programme

The global phase III clinical programme for gepotidacin in adults and
adolescents has now been completed. The programme comprises of three trials:

 

EAGLE-1 (non-inferiority urogenital gonorrhoea trial) compared the efficacy
and safety of gepotidacin to ceftriaxone plus azithromycin in approximately
600 patients with uncomplicated urogenital gonorrhoea.

 

EAGLE-2 and EAGLE-3 (non-inferiority uUTI trials) compared the efficacy and
safety of gepotidacin (1,500mg administered orally twice daily for five days)
to nitrofurantoin (100mg administered orally twice daily for five days).
Across both trials, the duration for participants was approximately 28 days,
and the primary endpoint was the combined clinical and microbiological
response at the ToC visit (days 10-13) in patients with qualifying
uropathogens susceptible to nitrofurantoin.

 

About Gepotidacin

Gepotidacin, discovered by GSK scientists, is an investigational bactericidal,
first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA
replication by a novel mechanism of action and binding site and for most
pathogens provides well-balanced inhibition of two different Type II
topoisomerase enzymes. This provides activity against most strains of target
uropathogens, (such as E. coli and S. saprophyticus), and N. gonorrhoeae,
including isolates resistant to several antibiotics. Due to the well-balanced
inhibition of two enzymes, gepotidacin target-specific mutations in both
enzymes are needed to significantly affect gepotidacin susceptibility.

 

GSK in infectious diseases

GSK has pioneered innovation in infectious diseases for over 70 years, and the
Company's pipeline of medicines and vaccines is one of the largest and most
diverse in the industry. GSK's expertise and capabilities in innovation,
access and stewardship position the Company uniquely to help prevent and
mitigate the challenge of antimicrobial resistance. In antimicrobials, in
addition to gepotidacin, GSK entered into an exclusive licence agreement with
Spero Therapeutics, Inc. in September 2022 to add tebipenem HBr, a late-stage
antibiotic and potential treatment for complicated urinary tract infections
(cUTI), to the pipeline. In March 2023, GSK announced an exclusive licence
agreement with Scynexis for Brexafemme (ibrexafungerp tablets), a
first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC)
and reduction in the incidence of recurrent VVC.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Sarah Clements     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

 1  World Health Organisation, Multi-drug resistant gonorrhoea. Available at:
https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea
(https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea)

 2  CDC data on file

 3  CDC, Sexually Transmitted Infections Surveillance. Available at:
https://www.cdc.gov/std/statistics/2022/default.htm#:~:text=In%202022%2C%20more%20than%202.5,from%20all%20STI%20prevention%20partners
(https://www.cdc.gov/std/statistics/2022/default.htm#:~:text=In%202022%2C%20more%20than%202.5,from%20all%20STI%20prevention%20partners)

 4  Centers for Disease Control and Prevention. Combating the Threat.
Available at:
https://www.cdc.gov/std/gonorrhea/drug-resistant/carb.htm#:~:text=There%20are%20more%20than%20500%2C000%20reported%20cases%20of,year%20are%20resistant%20to%20at%20least%20one%20antibiotic
(https://www.cdc.gov/std/gonorrhea/drug-resistant/carb.htm#:~:text=There%20are%20more%20than%20500%2C000%20reported%20cases%20of,year%20are%20resistant%20to%20at%20least%20one%20antibiotic)
.

 5  The Lancet, Oral gepotidacin versus nitrofurantoin in patients with
uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised,
controlled, double-blind, double-dummy, phase 3, non-inferiority trials,
available at:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02196-7/abstract

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGMDDVKGDZM